Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ:TARS
Want to see TARS full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.16Last Year’s EPS
-0.48Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted robust commercial momentum for XTENVI with a strong Q1 showing (>$145M, >85% YoY growth), growing prescriber adoption, improving DTC engagement (+~40% QoQ high-value activity), pipeline progress with two Phase II programs initiated and reiterated full-year guidance. Headwinds were largely expected and manageable: seasonal/deductible effects and weather impact in Q1, retreatment rates still progressing toward steady-state (~20%), limited near-term international royalties, and the one-time nature of a China milestone. Management emphasized continued execution, targeted commercial investments (Key Account Leaders), and confidence in achieving guidance and future growth drivers.Company Guidance
Strong XTENVI Sales Growth
XTENVI net product sales of $145.4 million in Q1 2026, up more than 85% year-over-year, reflecting expanding ECP utilization and consistent patient outcomes.
Reaffirmed Full-Year Financial Guidance
Full-year 2026 guidance reiterated: net product sales of $670 million to $700 million, SG&A $545 million to $565 million (including ~$40 million stock-based comp), R&D $115 million to $135 million (including ~$20 million stock-based comp), and gross margins of approximately 93%.
Commercial Momentum — Prescriber and Prescribing Depth
Nearly half of the 15,000 target ECPs prescribed XTENVI at least once a week (up ~10% from Q4 2025), with increasing depth of prescribing and mid-to-high teens retreatment rates trending toward a steady-state target of ~20%.
Direct-to-Consumer (DTC) Performance and Digital Engagement
DTC campaign delivering ROI at the higher end of benchmarks; xtenvi.com high-value engagement (quiz completion, Find a Doctor) up nearly 40% quarter-over-quarter and millions of website visitors driving patient funnel expansion.
Pipeline Progress — Phase II Initiations
Initiated CALLIOPE, an approximately 700-participant Phase II trial of TPO5 for potential Lyme disease prevention (top-line data expected in 2027). Also initiated the Phase II CORE study for TPO4 in ocular rosacea with top-line data expected in 2027.
One-Time License Milestone and Regulatory Win in Greater China
License fees and collaboration revenues of $16.7 million in Q1, including a one-time $15 million regulatory milestone from Grand Pharma following approval of TPO3 for DB in Greater China—supporting future royalty potential and regional commercial expansion.
Commercial Execution and Sales Force Enhancements
Preparing to deploy Key Account Leaders (~17–20 hires) targeted to high-opportunity practices to further increase depth of prescribing; management expects incremental impact beginning in 3Q/2H 2026.
Competitive and Market Positioning
Management reports XTENVI outperformed peers on prescription trends (peers saw double-digit declines vs Tarsus' low-single-digit declines in comparable metrics) and entering Q2 prescriptions rebounded to all-time highs.
TARS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TARS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 23, 2026 | $69.59 | $75.01 | +7.79% |
Nov 04, 2025 | $71.50 | $68.20 | -4.62% |
Aug 06, 2025 | $41.64 | $47.95 | +15.15% |
May 01, 2025 | $50.30 | $47.36 | -5.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Tarsus Pharmaceuticals, Inc. (TARS) report earnings?
Tarsus Pharmaceuticals, Inc. (TARS) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Tarsus Pharmaceuticals, Inc. (TARS) earnings time?
Tarsus Pharmaceuticals, Inc. (TARS) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TARS EPS forecast?
TARS EPS forecast for the fiscal quarter 2026 (Q2) is -0.16.